1%奥昔沙星乳膏治疗脓疱病：一项多中心、随机、安慰剂和瑞他帕林对照的临床试验。
Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial.
作者信息
Gropper Savion, Albareda Nuria, Chelius Klaus, Kruger Dawie, Mitha Ismail, Vahed Yacoob, Gani Mashra, García-Alonso Fernando
机构信息
Ferrer Internacional SA, Barcelona, Spain.
出版信息
Future Microbiol. 2014;9(9):1013-23. doi: 10.2217/fmb.14.78.
AIM
We compared the efficacy and safety of ozenoxacin (a new nonfluorinated quinolone) 1% cream with placebo in the treatment of impetigo.
PATIENTS & METHODS: In a randomized, double-blind, multicenter study, patients received ozenoxacin cream or placebo cream twice daily for 5 days (a third group received retapamulin 1% ointment as a control). Clinical, microbiological and laboratory evaluations were performed during follow-up (over 2 weeks).
RESULTS
Ozenoxacin was superior to placebo (success rate 34.8 vs 19.2%; p = 0.003). Microbiological success was 70.8% for ozenoxacin and 38.2% for placebo after 3-4 days and 79.2% versus 56.6% after 6-7 days. Ozenoxacin produced more rapid microbiological clearance than retapamulin. All treatments were well tolerated.
CONCLUSION
Ozenoxacin 1% cream was effective and safe in the treatment of impetigo.
目的
我们比较了1%奥扎沙星乳膏（一种新型非氟喹诺酮类药物）与安慰剂治疗脓疱病的疗效和安全性。
患者与方法
在一项随机、双盲、多中心研究中，患者每日两次外用奥扎沙星乳膏或安慰剂乳膏，持续5天（第三组外用1%瑞他帕林软膏作为对照）。在随访期间（超过2周）进行临床、微生物学和实验室评估。
结果
奥扎沙星优于安慰剂（成功率分别为34.8%和19.2%；p = 0.003）。3 - 4天后，奥扎沙星的微生物学清除成功率为70.8%，安慰剂为38.2%；6 - 7天后，分别为79.2%和56.6%。奥扎沙星比瑞他帕林产生更快的微生物学清除效果。所有治疗耐受性良好。
结论
1%奥扎沙星乳膏治疗脓疱病有效且安全。
Zotero 插件